Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation
Publication in refereed journal


Times Cited
Web of Science20WOS source URL (as at 17/09/2021) Click here for the latest count
Altmetrics Information
.

Other information
AbstractPost-liver transplantation tumor recurrence is a major challenge for hepatocellular carcinoma (HCC) recipients. We aimed to identify early-phase circulating microRNAs after liver transplantation for predicting tumor recurrence and survival of HCC recipients. Circulating microRNA profiles at early-phase (2-hour after portal vein reperfusion) after liver transplantation were compared between HCC recipients with (n=4) and without tumor recurrence (n=8) by microarray analyses. Candidate microRNAs were validated in 62 HCC recipients by quantitative RT-PCR. The prognostic values of microRNAs for tumor recurrence and survival were examined. Simulated in vitro ischemia-reperfusion injury models were employed to characterize the possible mechanism of up-regulation of circulating microRNAs. Our results showed that up-regulation of circulating miR-148a, miR-1246 or miR-1290 at early-phase was significantly associated with HCC recurrence after liver transplantation. Among them, miR-148a (p=0.030) and miR-1246 (p=0.009) were significant predictors of HCC recurrence. MiR-1246 was an independent predictor of overall (p=0.023) and disease-free survival (p=0.020) of HCC recipients. The level of early-phase circulating miR-1246 was positively correlated with serum AST and ALT levels in HCC recipients after liver transplantation. The expression of hepatic miR-1246 was positively correlated with TNF alpha mRNA. In vitro experiments indicated that injury-induced activation and differentiation of macrophages significantly elevated the expression and secretion of miR-1246. In conclusion, early-phase circulating miR-1246 is an indicator of hepatic injury and a novel prognostic biomarker for tumor recurrence and survival of HCC recipients after liver transplantation.
All Author(s) ListNg KTP, Lo CM, Wong N, Li CX, Qi X, Liu XB, Geng W, Yeung OWH, Ma YY, Chan SC, Man K
Journal nameOncotarget
Detailed descriptionDOI: 10.18632/oncotarget.7627.
Year2016
Month4
Day12
Volume Number7
Issue Number15
PublisherIMPACT JOURNALS LLC
Pages19824 - 19839
ISSN1949-2553
LanguagesEnglish-United Kingdom
Keywordsearly-phase; HCC recurrence; liver transplantation; macrophage activation; miR-1246
Web of Science Subject CategoriesCell Biology; Oncology

Last updated on 2021-18-09 at 00:26